These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 18216478)

  • 1. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
    Wu KL; Heule F; Lam K; Sonneveld P
    J Am Acad Dermatol; 2006 Nov; 55(5):897-900. PubMed ID: 17052502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
    Obeid KM; Ferrara R; Sharma M
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
    [No Abstract]   [Full Text] [Related]  

  • 5. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistent supravenous eruption induced by intravenous bortezomib therapy.
    Mataix J; Betlloch I; Palmero F; Romero A
    Br J Dermatol; 2008 Apr; 158(4):863-4. PubMed ID: 18284402
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
    Dehesa L; Bastida J; Limeres-González M; Campos-Adsuar C; Gómez-Duaso J
    Clin Exp Dermatol; 2009 Dec; 34(8):e1031-2. PubMed ID: 20055832
    [No Abstract]   [Full Text] [Related]  

  • 9. Bortezomib-induced histiocytoid Sweet syndrome.
    Murase JE; Wu JJ; Theate I; Cole GW; Barr RJ; Dyson SW
    J Am Acad Dermatol; 2009 Mar; 60(3):496-7. PubMed ID: 19231647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
    Rosiñol L; Montoto S; Cibeira MT; Bladé J
    Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin lesions induced by bortezomib.
    Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
    Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 14. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
    Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
    Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.
    Min CK; Lee S; Kim YJ; Eom KS; Lee JW; Min WS; Kim CC; Cho CS; Park G
    Eur J Haematol; 2006 Mar; 76(3):265-8. PubMed ID: 16451401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
    Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
    J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
    [No Abstract]   [Full Text] [Related]  

  • 17. [Aggravated post-herpetic neuralgia due to bortezomib].
    Kirizume K; Imataki O; Shintani T; Fujihara S; Waki F; Ohue Y; Ohnishi H
    Rinsho Ketsueki; 2008 May; 49(5):331-4. PubMed ID: 18572810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bortezomib-induced eruption: Sweet syndrome? Two case reports].
    Thuillier D; Lenglet A; Chaby G; Royer R; Vaida I; Viseux V; Dadban A; Billet A; Christophe O; Chatelain D; Marolleau JP; Lok C; Damaj G
    Ann Dermatol Venereol; 2009 May; 136(5):427-30. PubMed ID: 19442799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bortezomib-induced acute neutrophilic dermatosis].
    Tanguy-Schmidt A; Avenel-Audran M; Croué A; Lissandre S; Dib M; Zidane-Marinnes M; Moles MP; Hunault-Berger M
    Ann Dermatol Venereol; 2009 May; 136(5):443-6. PubMed ID: 19442803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib-associated rash: a new recognizable and avoidable side-effect.
    Villarrubia B; Betlloch I; Mataix J; Lucas A; Botella C
    Br J Dermatol; 2007 Apr; 156(4):784-5. PubMed ID: 17286633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.